News
KRRO
14.10
+2.99%
0.41
Weekly Report: what happened at KRRO last week (0406-0410)?
Weekly Report · 1d ago
Korro Bio grants new-hire inducement option for 15,000 shares at $13.46 each
Reuters · 3d ago
KORRO BIO REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 3d ago
Weekly Report: what happened at KRRO last week (0330-0403)?
Weekly Report · 04/06 09:36
Lynx1 Capital Management acquires Korro Bio shares worth $0 million
Reuters · 04/02 16:01
Korro Bio initial beneficial ownership filing shows Lynx1 Capital Management as 10% owner
Reuters · 04/02 16:01
Weekly Report: what happened at KRRO last week (0323-0327)?
Weekly Report · 03/30 09:36
Weekly Report: what happened at KRRO last week (0316-0320)?
Weekly Report · 03/23 09:34
Korro Bio Inc. publishes corporate presentation on RNA editing genetic medicines and pipeline milestones
Reuters · 03/19 16:06
Weekly Report: what happened at KRRO last week (0309-0313)?
Weekly Report · 03/16 09:34
Korro Bio files to sell 7.65M shares of common stock for holders
TipRanks · 03/13 21:10
Friday 3/13 Insider Buying Report: LOAR, KRRO
NASDAQ · 03/13 17:45
Korro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost Outlook
Benzinga · 03/13 17:02
Korro Bio Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones · 03/13 13:33
Cantor Fitzgerald Maintains Overweight on Korro Bio, Raises Price Target to $22
Benzinga · 03/13 13:23
RBC Capital Keeps Their Hold Rating on Korro Bio (KRRO)
TipRanks · 03/13 12:28
Piper Sandler Keeps Their Buy Rating on Korro Bio (KRRO)
TipRanks · 03/13 12:28
Analysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB), Korro Bio (KRRO) and Pharming Group (PHAR)
TipRanks · 03/13 12:10
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 03/13 12:05
Korro Bio Raised to Outperform From Market Perform by Raymond James
Dow Jones · 03/13 12:01
More
Webull provides a variety of real-time KRRO stock news. You can receive the latest news about Korro Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About KRRO
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.